Familial Dysautonomia Differential Diagnoses

1. Axelrod FB. Familial dysautonomia. Muscle Nerve. 2004 Mar. 29(3):352-63. [QxMD MEDLINE Link].

2. Axelrod FB. A world without pain or tears. Clin Auton Res. 2006 Apr. 16(2):90-7. [QxMD MEDLINE Link].

3. Riley CM, Day RL, Greeley DM. Central autonomic dysfunction with defective lacrimation: report of five cases. Pediatrics. 1949. Vol. 3: 468-77.

4. Anderson SL, Coli R, Daly IW, et al. Familial dysautonomia is caused by mutations of the IKAP gene. Am J Hum Genet. 2001 Mar. 68(3):753-8. [QxMD MEDLINE Link].

5. Leyne M, Mull J, Gill SP, et al. Identification of the first non-Jewish mutation in familial Dysautonomia. Am J Med Genet A. 2003 May 1. 118A(4):305-8. [QxMD MEDLINE Link].

6. Slaugenhaupt SA, Blumenfeld A, Gill SP, et al. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet. 2001 Mar. 68(3):598-605. [QxMD MEDLINE Link].

7. Pearson J, Pytel BA, Grover-Johnson N, et al. Quantitative studies of dorsal root ganglia and neuropathologic observations on spinal cords in familial dysautonomia. J Neurol Sci. 1978 Jan. 35(1):77-92. [QxMD MEDLINE Link].

8. Axelrod FB, Goldberg JD, Ye XY, et al. Survival in familial dysautonomia: Impact of early intervention. J Pediatr. 2002 Oct. 141(4):518-23. [QxMD MEDLINE Link].

9. Brunt PW, McKusick VA. Familial dysautonomia. A report of genetic and clinical studies, with a review of the literature. Medicine (Baltimore). 1970 Sep. 49(5):343-74. [QxMD MEDLINE Link].

10. Porges RF, Axelrod FB, Richards M. Pregnancy in familial dysautonomia. Am J Obstet Gynecol. 1978 Nov 1. 132(5):485-8. [QxMD MEDLINE Link].

11. Elkayam L, Matalon A, Tseng CH, et al. Prevalence and severity of renal disease in familial dysautonomia. Am J Kidney Dis. 2006 Nov. 48(5):780-6. [QxMD MEDLINE Link].

12. Clayson D, Welton W, Axelrod FB. Personality development and familial dysautonomia. Pediatrics. 1980 Feb. 65(2):269-74. [QxMD MEDLINE Link].

13. Sands SA, Giarraffa P, Jacobson CM, et al. Familial dysautonomia's impact on quality of life in childhood, adolescence, and adulthood. Acta Paediatr. 2006 Apr. 95(4):457-62. [QxMD MEDLINE Link].

14. Welton W, Clayson D, Axelrod FB, et al. Intellectual development and familial dysautonomia. Pediatrics. 1979 May. 63(5):708-12. [QxMD MEDLINE Link].

15. Axelrod FB, Iyer K, Fish I, et al. Progressive sensory loss in familial dysautonomia. Pediatrics. 1981 Apr. 67(4):517-22. [QxMD MEDLINE Link].

16. Blumenfeld A, Slaugenhaupt SA, Axelrod FB, et al. Localization of the gene for familial dysautonomia on chromosome 9 and definition of DNA markers for genetic diagnosis. Nat Genet. 1993 Jun. 4(2):160-4. [QxMD MEDLINE Link].

17. Axelrod FB, Liebes L, Gold-Von Simson G, Mendoza S, Mull J, Leyne M, et al. Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia. Pediatr Res. 2011 Nov. 70(5):480-3. [QxMD MEDLINE Link]. [Full Text].

18. Cohen-Kupiec R, Pasmanik-Chor M, Oron-Karni V, Weil M. Effects of IKAP/hELP1 deficiency on gene expression in differentiating neuroblastoma cells: implications for familial dysautonomia. PLoS One. 2011 Apr 29. 6(4):e19147. [QxMD MEDLINE Link]. [Full Text].

19. Axelrod FB, Goldstein DS, Holmes C, et al. Pattern of plasma levels of catecholamines in familial dysautonomia. Clin Auton Res. 1996 Aug. 6(4):205-9. [QxMD MEDLINE Link].

20. Axelrod FB, Goldberg JD, Rolnitzky L, et al. Fludrocortisone in patients with familial dysautonomia--assessing effect on clinical parameters and gene expression. Clin Auton Res. 2005 Aug. 15(4):284-91. [QxMD MEDLINE Link].

21. Axelrod,FB, D’Amico,RA. Familial Dysautonomia. Fraunfelder FT, Roy H, Eds. Ocular Therapy 2. Philadelphia, PA: WB Saunders; 1985. 200-1.

22. Diamond GA, D'Amico RA, Axelrod FB. Optic nerve dysfunction in familial dysautonomia. Am J Ophthalmol. 1987 Dec 15. 104(6):645-8. [QxMD MEDLINE Link].

23. Mendoza-Santiesteban CE, Hedges TR 3rd, Norcliffe-Kaufmann L, Warren F, Reddy S, Axelrod FB, et al. Clinical Neuro-ophthalmic Findings in Familial Dysautonomia. J Neuroophthalmol. 2011 Sep 13. [QxMD MEDLINE Link].

24. Mendoza-Santiesteban CE, Palma JA, Hedges TR 3rd, Laver NV, Farhat N, Norcliffe-Kaufmann L, et al. Pathological Confirmation of Optic Neuropathy in Familial Dysautonomia. J Neuropathol Exp Neurol. 2017 Mar 1. 76 (3):238-244. [QxMD MEDLINE Link].

25. Bernardi L, Hilz M, Stemper B, et al. Respiratory and cerebrovascular responses to hypoxia and hypercapnia in familial dysautonomia. Am J Respir Crit Care Med. 2003 Jan 15. 167(2):141-9. [QxMD MEDLINE Link].

26. Maayan C, Carley DW, Axelrod FB, et al. Respiratory system stability and abnormal carbon dioxide homeostasis. J Appl Physiol. 1992 Mar. 72(3):1186-93. [QxMD MEDLINE Link].

27. Roach ES, Miller VS, eds. Neurocutaneous Disorders. Cambridge University Press; 2004.

28. Aragona P, Papa V, Micali A, et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002 Feb. 86(2):181-4. [QxMD MEDLINE Link].

29. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004 Feb. 137(2):337-42. [QxMD MEDLINE Link].

30. Anderson SL, Qiu J, Rubin BY. Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia. Biochem Biophys Res Commun. 2003 Jun 20. 306(1):303-9. [QxMD MEDLINE Link].

31. Ilsar M, Hartstein ME, Maayan C. Punctal occlusion in patients with familial dysautonomia. Ann Ophthalmology. 1998. 30(6):375-378.

32. Rosenthal P, Cotter JM, Baum J. Treatment of persistent corneal epithelial defect with extended wear of a fluid-ventilated gas-permeable scleral contact lens. Am J Ophthalmol. 2000 Jul. 130(1):33-41. [QxMD MEDLINE Link].

33. Le HG, Tang M, Ridges R, Huang D, Jacobs DS. Pilot Study for OCT Guided Design and Fit of a Prosthetic Device for Treatment of Corneal Disease. J Ophthalmol. 2012. 2012:812034. [QxMD MEDLINE Link]. [Full Text].

34. Bonini S, Lambiase A, Rama P, et al. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000 Jul. 107(7):1347-51; discussion 1351-2. [QxMD MEDLINE Link].

35. Matsumoto Y, Dogru M, Goto E, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004 Jun. 111(6):1115-20. [QxMD MEDLINE Link].

36. Kojima T, Ishida R, Dogru M, et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol. 2005 Feb. 139(2):242-6. [QxMD MEDLINE Link].

37. Chen HJ, Pires RT, Tseng SC. Amniotic membrane transplantation for severe neurotrophic corneal ulcers. Br J Ophthalmol. 2000 Aug. 84(8):826-33. [QxMD MEDLINE Link]. [Full Text].

38. Tseng SC, Espana EM, Kawakita T, et al. How does amniotic membrane work?. Ocul Surf. 2004 Jul. 2(3):177-87. [QxMD MEDLINE Link].

39. Dohlman C, Waller S, Netland P. Keratoprosthesis Surgery. Lindquist T, Lindstrom R, eds. Ophthalmic Surgery. 1996. Vol L: 1-32.

40. Ngai J, Kreynin I, Kim JT, et al. Anesthesia management of familial dysautonomia. Paediatr Anaesth. 2006 Jun. 16(6):611-20. [QxMD MEDLINE Link].

41. Axelrod FB. Familial dysautonomia. Burg FD, Ingelfinger JR, Polin RA, eds. Current Pediatric Therapy. 15th ed. Philadelphia, Pa: WB Saunders Co; 1996. 91-94.

42. Axelrod FB. Familial dysautonomia: a review of the current pharmacological treatments. Expert Opin Pharmacother. 2005 Apr. 6(4):561-7. [QxMD MEDLINE Link].

Robert A D'Amico, MD, FACS Chairman, Department of Ophthalmology, Richmond University Medical Center; Clinical Professor, Department of Ophthalmology, New York University School of Medicine

Robert A D'Amico, MD, FACS is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, American Medical Association, Association for Research in Vision and Ophthalmology, Association of University Professors of Ophthalmology, Cornea Society, International Society for Genetic Eye Diseases and Retinoblastoma, Medical Society of the State of New York, New York Academy of Medicine, Transplantation Society, Xenotransplantation Society

Disclosure: Nothing to disclose.

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Hampton Roy, Sr, MD † Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Andrew W Lawton, MD Neuro-Ophthalmology, Ochsner Health Services

Andrew W Lawton, MD is a member of the following medical societies: American Academy of Ophthalmology, Arkansas Medical Society, Southern Medical Association

Disclosure: Nothing to disclose.

Felicia B Axelrod, MD Director of Dysautonomia Treatment and Evaluation Center, Carl Seaman Family Professor for Dysautonomia Treatment and Research, Professor, Departments of Pediatrics and Neurology, New York University School of Medicine

Felicia B Axelrod, MD is a member of the following medical societies: American Academy of Pediatrics, American Autonomic Society, American Medical Association, American Pediatric Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article